Drug makers stalling on 2012 business plan

Published: 2011-12-01 07:00:00

Updated: 2011-12-01 07:00:00

Weighed down by the imminent large price cuts and Assembly’s ratification of the new Korea-U.S. free trade agreement, domestic pharmaceutical firms are delaying the formulation of their business plans for next year.

At this time of the year, Korean companies usually flesh out key components of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK